These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18267049)

  • 21. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial.
    Bhandari N; Sharma P; Glass RI; Ray P; Greenberg H; Taneja S; Saksena M; Rao CD; Gentsch JR; Parashar U; Maldonado Y; Ward RL; Bhan MK
    Vaccine; 2006 Jul; 24(31-32):5817-23. PubMed ID: 16735085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum IgA levels induced by rotavirus natural infection, but not following immunization with the RRV-TV vaccine (Rotashield), correlate with protection.
    González R; Franco M; Sarmiento L; Romero M; Schael IP
    J Med Virol; 2005 Aug; 76(4):608-12. PubMed ID: 15977224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human rotavirus virus-like particle vaccines evaluated in a neonatal gnotobiotic pig model of human rotavirus disease.
    Azevedo MP; Vlasova AN; Saif LJ
    Expert Rev Vaccines; 2013 Feb; 12(2):169-81. PubMed ID: 23414408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Passive protection to bovine rotavirus (BRV) infection induced by a BRV VP8* produced in plants using a TMV-based vector.
    Pérez Filgueira DM; Mozgovoj M; Wigdorovitz A; Dus Santos MJ; Parreño V; Trono K; Fernandez FM; Carrillo C; Babiuk LA; Morris TJ; Borca MV
    Arch Virol; 2004 Dec; 149(12):2337-48. PubMed ID: 15338319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reductions in cross-neutralizing antibody responses in infants after attenuation of the human rotavirus vaccine candidate 89-12.
    Ward RL; Kirkwood CD; Sander DS; Smith VE; Shao M; Bean JA; Sack DA; Bernstein DI
    J Infect Dis; 2006 Dec; 194(12):1729-36. PubMed ID: 17109346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine.
    Ciarlet M; Sani-Grosso R; Yuan G; Liu GF; Heaton PM; Gottesdiener KM; Arredondo JL; Schödel F
    Pediatr Infect Dis J; 2008 Oct; 27(10):874-80. PubMed ID: 18756184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Impact of rotavirus vaccines in developing countries].
    Delacour H
    Med Trop (Mars); 2009 Aug; 69(4):327-32. PubMed ID: 19725379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rotavirus vaccines: is the second time the charm?
    Ward RL
    Curr Opin Investig Drugs; 2005 Aug; 6(8):798-803. PubMed ID: 16121686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of a plant-derived edible rotavirus subunit vaccine transformed over fifty generations.
    Li JT; Fei L; Mou ZR; Wei J; Tang Y; He HY; Wang L; Wu YZ
    Virology; 2006 Dec 5-20; 356(1-2):171-8. PubMed ID: 16956640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective effects of natural rotavirus infection.
    Velázquez FR
    Pediatr Infect Dis J; 2009 Mar; 28(3 Suppl):S54-6. PubMed ID: 19252424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brucella spp. lumazine synthase as a bovine rotavirus antigen delivery system.
    Bellido D; Craig PO; Mozgovoj MV; Gonzalez DD; Wigdorovitz A; Goldbaum FA; Dus Santos MJ
    Vaccine; 2009 Jan; 27(1):136-45. PubMed ID: 18973781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rotavirus virus-like particles (RV-VLPs) vaccines: An update.
    Changotra H; Vij A
    Rev Med Virol; 2017 Nov; 27(6):. PubMed ID: 29048711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LAP
    Rey LM; Gil JÁ; Mateus J; Rodríguez LS; Rondón MA; Ángel J; Franco MA
    J Virol; 2019 Oct; 93(19):. PubMed ID: 31292251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Yeast expression of the VP8* fragment of the rotavirus spike protein and its use as immunogen in mice.
    Andrés I; Rodríguez-Díaz J; Buesa J; Zueco J
    Biotechnol Bioeng; 2006 Jan; 93(1):89-98. PubMed ID: 16193515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.
    Pasquevich KA; Estein SM; García Samartino C; Zwerdling A; Coria LM; Barrionuevo P; Fossati CA; Giambartolomei GH; Cassataro J
    Infect Immun; 2009 Jan; 77(1):436-45. PubMed ID: 18981242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments.
    van der Vaart JM; Pant N; Wolvers D; Bezemer S; Hermans PW; Bellamy K; Sarker SA; van der Logt CP; Svensson L; Verrips CT; Hammarstrom L; van Klinken BJ
    Vaccine; 2006 May; 24(19):4130-7. PubMed ID: 16616802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amount of maternal rotavirus-specific antibodies influence the outcome of rotavirus vaccination of newborn mice with virus-like particles.
    Johansson E; Istrate C; Charpilienne A; Cohen J; Hinkula J; Poncet D; Svensson L; Johansen K
    Vaccine; 2008 Feb; 26(6):778-85. PubMed ID: 18191310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rotavirus immune responses and correlates of protection.
    Angel J; Franco MA; Greenberg HB
    Curr Opin Virol; 2012 Aug; 2(4):419-25. PubMed ID: 22677178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Vaccine prevention of Rotavirus infection].
    Swennen B; Levy J
    Rev Med Brux; 2006 Sep; 27(4):S333-7. PubMed ID: 17091899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs.
    Patel MM; Parashar UD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S291-9. PubMed ID: 19817612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.